News Information
Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset
Release time:
2026-01-12

PepLib aims to promote the development and accessibility of innovative peptide drugs, benefiting global patients and human health while keeping costs low.
Contact
Copyright©2023 Zonsen PepLib Biotech Inc. This website supports IPV6
Business License